Literature DB >> 17566103

Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide.

Nicholas G Nickols1, Peter B Dervan.   

Abstract

Androgen receptor (AR) is essential for the growth and progression of prostate cancer in both hormone-sensitive and hormone-refractory disease. A DNA-binding polyamide that targets the consensus androgen response element binds the prostate-specific antigen (PSA) promoter androgen response element, inhibits androgen-induced expression of PSA and several other AR-regulated genes in cultured prostate cancer cells, and reduces AR occupancy at the PSA promoter and enhancer. Down-regulation of PSA by this polyamide was comparable to that produced by the synthetic antiandrogen bicalutamide (Casodex) at the same concentration. Genome-wide expression analysis reveals that a similar number of transcripts are affected by treatment with the polyamide and with bicalutamide. Direct inhibition of the AR-DNA interface by sequence-specific DNA binding small molecules could offer an alternative approach to antagonizing AR activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17566103      PMCID: PMC1965528          DOI: 10.1073/pnas.0704217104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  43 in total

1.  Footprinting methods for analysis of pyrrole-imidazole polyamide/DNA complexes.

Authors:  J W Trauger; P B Dervan
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

2.  The program of androgen-responsive genes in neoplastic prostate epithelium.

Authors:  Peter S Nelson; Nigel Clegg; Hugh Arnold; Camari Ferguson; Michael Bonham; James White; Leroy Hood; Biaoyang Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-16       Impact factor: 11.205

Review 3.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

4.  Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA.

Authors:  B F Luisi; W X Xu; Z Otwinowski; L P Freedman; K R Yamamoto; P B Sigler
Journal:  Nature       Date:  1991-08-08       Impact factor: 49.962

5.  DNA sequence-specific polyamides alleviate transcription inhibition associated with long GAA.TTC repeats in Friedreich's ataxia.

Authors:  Ryan Burnett; Christian Melander; James W Puckett; Leslie S Son; Robert D Wells; Peter B Dervan; Joel M Gottesfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-20       Impact factor: 11.205

6.  Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice.

Authors:  K A Klein; R E Reiter; J Redula; H Moradi; X L Zhu; A R Brothman; D J Lamb; M Marcelli; A Belldegrun; O N Witte; C L Sawyers
Journal:  Nat Med       Date:  1997-04       Impact factor: 53.440

7.  TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer.

Authors:  Scott A Tomlins; Rohit Mehra; Daniel R Rhodes; Lisa R Smith; Diane Roulston; Beth E Helgeson; Xuhong Cao; John T Wei; Mark A Rubin; Rajal B Shah; Arul M Chinnaiyan
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

8.  Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.

Authors:  Michael G Oefelein; Piyush K Agarwal; Martin I Resnick
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

9.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

10.  Allosteric inhibition of zinc-finger binding in the major groove of DNA by minor-groove binding ligands.

Authors:  Doan H Nguyen-Hackley; Elizabeth Ramm; Christina M Taylor; J Keith Joung; Peter B Dervan; Carl O Pabo
Journal:  Biochemistry       Date:  2004-04-06       Impact factor: 3.162

View more
  90 in total

1.  Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions.

Authors:  Kush Dalal; Meixia Che; Nanette S Que; Aishwariya Sharma; Rendong Yang; Nada Lallous; Hendrik Borgmann; Deniz Ozistanbullu; Ronnie Tse; Fuqiang Ban; Huifang Li; Kevin J Tam; Mani Roshan-Moniri; Eric LeBlanc; Martin E Gleave; Daniel T Gewirth; Scott M Dehm; Artem Cherkasov; Paul S Rennie
Journal:  Mol Cancer Ther       Date:  2017-08-03       Impact factor: 6.261

2.  Pharmacokinetics of Py-Im polyamides depend on architecture: cyclic versus linear.

Authors:  Jevgenij A Raskatov; Amanda E Hargrove; Alex Y So; Peter B Dervan
Journal:  J Am Chem Soc       Date:  2012-04-24       Impact factor: 15.419

Review 3.  Suppression of tumor and metastasis progression through the scaffolding functions of SSeCKS/Gravin/AKAP12.

Authors:  Irwin H Gelman
Journal:  Cancer Metastasis Rev       Date:  2012-12       Impact factor: 9.264

4.  Targeting CREB for cancer therapy: friend or foe.

Authors:  Xiangshu Xiao; Bingbing X Li; Bryan Mitton; Alan Ikeda; Kathleen M Sakamoto
Journal:  Curr Cancer Drug Targets       Date:  2010-06       Impact factor: 3.428

Review 5.  Small molecule inhibitors as probes for estrogen and androgen receptor action.

Authors:  David J Shapiro; Chengjian Mao; Milu T Cherian
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

6.  An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors.

Authors:  Jerzy O Szablowski; Jevgenij A Raskatov; Peter B Dervan
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

7.  Modulation of topoisomerase IIα expression and chemosensitivity through targeted inhibition of NF-Y:DNA binding by a diamino p-anisyl-benzimidazole (Hx) polyamide.

Authors:  Luke Pett; Konstantinos Kiakos; Vijay Satam; Pravin Patil; Sarah Laughlin-Toth; Matthew Gregory; Michael Bowerman; Kevin Olson; Mia Savagian; Megan Lee; Moses Lee; W David Wilson; Daniel Hochhauser; John A Hartley
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2016-10-24       Impact factor: 4.490

Review 8.  Rationale for the development of alternative forms of androgen deprivation therapy.

Authors:  Sangeeta Kumari; Dhirodatta Senapati; Hannelore V Heemers
Journal:  Endocr Relat Cancer       Date:  2017-05-31       Impact factor: 5.678

9.  Direct inhibition of hypoxia-inducible transcription factor complex with designed dimeric epidithiodiketopiperazine.

Authors:  Katherine M Block; Hui Wang; Lajos Z Szabó; Nathan W Polaske; Laura K Henchey; Ramin Dubey; Swati Kushal; Csaba F László; Joshua Makhoul; Zuohe Song; Emmanuelle J Meuillet; Bogdan Z Olenyuk
Journal:  J Am Chem Soc       Date:  2009-12-23       Impact factor: 15.419

10.  Next generation hairpin polyamides with (R)-3,4-diaminobutyric acid turn unit.

Authors:  Christian Dose; Michelle E Farkas; David M Chenoweth; Peter B Dervan
Journal:  J Am Chem Soc       Date:  2008-05-07       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.